Find uplifting stories about heroes, innovations, and solutions
3858 results for "pancreatic cancer"
A newly approved pill nearly doubles survival time for patients with advanced pancreatic cancer, offering real hope for one of the deadliest cancer types. The breakthrough targets a protein that drives tumor growth in 95% of pancreatic cancer cases.
Scientists at Johns Hopkins developed a vaccine that may prevent pancreatic cancer before it starts, triggering lasting immune responses in 90% of high-risk patients. None of the 20 participants developed cancer during the study, and some saw their precancerous cysts shrink or disappear.
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
A daily pill called daraxonrasib helped control cancer in 90% of pancreatic cancer patients during early trials, offering new hope for a disease that has had few effective treatments. The drug targets genetic mutations found in over 90% of pancreatic cancers.
A breakthrough drug called daraxonrasib doubled survival time for pancreatic cancer patients compared to chemotherapy, offering new hope for one of the deadliest cancers. The treatment targets the genetic mutation behind 90% of pancreatic cancers and causes far fewer severe side effects.
Scientists in Spain eliminated pancreatic tumors in mice using a triple-drug therapy, with no cancer returning over 200 days. The breakthrough targets the deadliest form of pancreatic cancer and could reshape treatment if human trials succeed.
A new daily pill has earned FDA approval after clinical trials showed it doubled survival time for pancreatic cancer patients when combined with chemotherapy. The drug blocks a mutated protein that drives tumor growth in most pancreatic cancer cases.
A breakthrough drug for pancreatic cancer has doubled survival times in clinical trials, and ten hospitals across three states are now offering early access to eligible patients. The treatment targets specific genetic mutations found in over 90% of pancreatic cancers.
A breakthrough drug targeting previously "undruggable" KRAS mutations has approximately doubled survival time for metastatic pancreatic cancer patients compared to chemotherapy. The development marks a historic shift for a disease that affects over 90% of pancreatic cancer cases. --- ##
A breakthrough drug for pancreatic cancer has stunned researchers by controlling disease in 90% of patients who had already tried chemotherapy. The daily pill targets gene mutations found in nearly all pancreatic cancers, offering hope where treatment options have been scarce.
An experimental drug safely activated immune responses against pancreatic cancer in 90% of high-risk patients, offering hope for preventing one of the deadliest cancers. After two years, none of the participants developed cancer.
Scientists in Ireland have created the first complete "playbook" of pancreatic cancer, revealing why it's been so deadly and where new treatments could finally work. Their breakthrough approach targets multiple weak points at once, offering fresh hope for a disease that has resisted progress for decades.
Scientists at Oregon Health & Science University discovered that stress nerves help pancreatic tumors grow, opening doors to potential new treatments. The breakthrough could transform how we fight one of the deadliest cancers.
An experimental pill called daraxonrasib helped pancreatic cancer patients live nearly twice as long as those on standard chemotherapy. The breakthrough results, presented at a major cancer conference, mark a historic first for one of medicine's toughest cancers.
Scientists at Florida A&M University discovered an experimental compound that makes deadly pancreatic cancer cells essentially kill themselves. The treatment blocked over 90% of cancer cell movement, offering new hope for one of the most lethal cancers.
Scientists at Oregon Health & Science University just cracked a puzzle that's stumped cancer researchers for years: why pancreatic cancer fights off immunotherapy. The discovery could finally give patients new treatment options.
University of Pennsylvania researchers eliminated precancerous pancreatic cells in mice before they became tumors, nearly doubling survival time. It's the first proof that medical intervention can stop pancreatic cancer at its earliest stage.
Researchers discovered that pancreatic cancer cells depend on inflammation from damaged mitochondria to survive, and blocking this process kills tumors. The breakthrough could finally offer new treatment options for one of the deadliest cancers.
For the first time in three decades, patients with inoperable pancreatic cancer have a new treatment option. The FDA just approved Optune Pax, a wearable device you use at home that uses electric fields to kill cancer cells.
The FDA just approved Optune Pax, a new treatment option for people battling locally advanced pancreatic cancer. This approval brings fresh hope to patients facing one of the most challenging cancer diagnoses.
Showing 20 of 3858